Clinical characteristics and associated factors of qualitative olfactory dysfunction
- PMID: 37243721
- DOI: 10.4193/Rhin23.004
Clinical characteristics and associated factors of qualitative olfactory dysfunction
Abstract
Background: Although interest in qualitative olfactory dysfunction (OD), including parosmia and phantosmia, has been increasing since the COVID-19 pandemic, little is known about the clinical characteristics and associated factors of qualitative OD.
Methods: Adult patients with subjective smell disturbance who underwent both the olfactory questionnaire and psychophysical olfactory function test were retrospectively enrolled. Demographic and clinical characteristics were analysed according to the presence or absence of parosmia or phantosmia.
Results: Among a total of 753 patients with self-reported OD, 60 (8%) and 167 (22.2%) patients reported parosmia and phantosmia, respectively. Younger age and female sex were related to both parosmia and phantosmia. The frequency of parosmia was significantly higher in patients with post-viral OD (17.9%) than in patients with the sinonasal disease (5.5%), whereas that of phantosmia was not different according to aetiologies of OD. Patients with COVID-19 had significantly younger ages and higher TDI scores than those with other viral infections. Remarkably, patients with parosmia or phantosmia had significantly higher TDI scores than those without but experienced more disruption in daily life. In the multivariate analysis, younger age and higher TDI score were identified as independent factors associated with both parosmia and phantosmia, while the viral infection was associated with parosmia but not with phantosmia.
Conclusions: Patients with OD who have parosmia or phantosmia have higher odour sensitivity than those who do not, but experience more deterioration in the quality of life. Viral infection is a risk factor for parosmia but not for phantosmia.
Similar articles
-
Comparison of Patient Characteristics and Olfactory Sensitivity for Trigger Odorants in Parosmia and Phantosmia.Laryngoscope. 2024 Jul;134(7):3277-3285. doi: 10.1002/lary.31379. Epub 2024 Apr 5. Laryngoscope. 2024. PMID: 38578016
-
Parosmia in patients with post-infectious olfactory dysfunction in the era of COVID-19-associated olfactory impairment.HNO. 2024 Sep;72(9):649-656. doi: 10.1007/s00106-024-01470-7. Epub 2024 Jun 27. HNO. 2024. PMID: 38935276 Free PMC article.
-
Qualitative smell/taste disorders as sequelae of acute COVID-19.Neurol Sci. 2021 Dec;42(12):4921-4926. doi: 10.1007/s10072-021-05611-6. Epub 2021 Sep 23. Neurol Sci. 2021. PMID: 34557966 Free PMC article.
-
Parosmia and Phantosmia: Managing Quality Disorders.Curr Otorhinolaryngol Rep. 2023;11(1):19-26. doi: 10.1007/s40136-023-00441-w. Epub 2023 Jan 27. Curr Otorhinolaryngol Rep. 2023. PMID: 36721659 Free PMC article. Review.
-
Olfactory Nomenclature: An Orchestrated Effort to Clarify Terms and Definitions of Dysosmia, Anosmia, Hyposmia, Normosmia, Hyperosmia, Olfactory Intolerance, Parosmia, and Phantosmia/Olfactory Hallucination.ORL J Otorhinolaryngol Relat Spec. 2023;85(6):312-320. doi: 10.1159/000530211. Epub 2023 Apr 14. ORL J Otorhinolaryngol Relat Spec. 2023. PMID: 37062268 Free PMC article. Review.
Cited by
-
Parosmia: Pathophysiology and Management.Curr Allergy Asthma Rep. 2025 Jan 16;25(1):10. doi: 10.1007/s11882-024-01189-z. Curr Allergy Asthma Rep. 2025. PMID: 39821581 Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical